Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer

Sponsor
Shanghai JMT-Bio Inc.
Study ID
NCT05513664
Status
Unknown

Conditions

  • EGFR Exon20 Insertion Mutations
  • Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This study is a retrospective real-world study to evaluate the efficacy of Osimertinib for patients with advanced or metastatic EGFR 20exon insertion mutation (20ins) Non-Small Cell Lung Cancer.

Key Dates

Start date
Sep 30, 2022
Status verified
Jul 2022
Primary completion
Jun 30, 2023
Completion
Aug 31, 2023

Study Design

Enrollment
80 participants (estimated)

Primary Outcome Measure

1.Real world Objective Response Rate (rwORR) [ Time Frame: March 2017 to May 2022 ]

Central Contacts

Related Studies